---

LIVER FUNCTION TESTS (LFTs): A Comprehensive MD/DNB Pediatrics Review

---

1. DEFINITION AND LIMITATIONS

"The term liver biochemical tests is preferable to liver function tests because the most commonly used tests - the aminotransferases and alkaline phosphatase - do not measure a known function of the liver." - Sleisenger & Fordtran's, Chapter 73

Why LFTs Cannot Directly Measure Liver Function:

---

2. PHYSIOLOGY OF THE LIVER AND RATIONALE BEHIND EACH TEST

1. Chemical-metabolic system (hepatocytes) - tested by AST, ALT, LDH; also synthesizes >90% of serum proteins including all albumin
2. Reticuloendothelial system (Kupffer cells) - processes hemoglobin from lysed RBCs; biliverdin → bilirubin
3. Biliary secretory system (canalicular system) - excretes conjugated bilirubin; GGT and ALP sit on canalicular membranes

---

3. COMPONENTS OF THE LFT PANEL

3A. BILIRUBIN

Senescent RBCs → Reticuloendothelial System (spleen, liver Kupffer cells)
     ↓
Hemoglobin → Heme + Globin
     ↓
Heme oxygenase → Biliverdin + CO + Fe²⁺
     ↓
Biliverdin reductase → UNCONJUGATED BILIRUBIN (UCB)
     ↓ (lipid-soluble, bound to albumin in blood)
Hepatocyte uptake via OATP1B1/1B3 transport proteins
     ↓
Endoplasmic reticulum: B-UGT (bilirubin UDP-glucuronosyltransferase)
     ↓
CONJUGATED BILIRUBIN (CB) = bilirubin monoglucuronide + diglucuronide (water-soluble)
     ↓
Canalicular export via MRP2 (ATP-dependent - ONLY energy-dependent step)
     ↓
Bile → Intestine
     ↓
Bacteria: β-glucuronidase → UCB → Urobilinogen
     ↓
80% excreted in stool (stercobilin - brown color)
20% enterohepatic recirculation; small fraction → urine (urobilinogen)

---

3B. AMINOTRANSFERASES: AST (SGOT) AND ALT (SGPT)

• Elevated AST with normal ALT + elevated CK = muscle disease (DMD, myositis)
• In Wilson's disease presenting as ALF: AST/ALT ratio > 2 with ALP paradoxically LOW is characteristic
• Macro-AST: High molecular weight AST-immunoglobulin complex; causes persistent isolated AST elevation without liver disease

---

3C. ALKALINE PHOSPHATASE (ALP)

• Location: Canalicular membrane of hepatocytes, bile duct epithelium, bone osteoblasts, placenta, small intestine
• Normal range: Markedly age-dependent (CRITICAL in pediatrics)
• Mechanism of elevation in cholestasis: Bile acids stimulate synthesis of ALP, which is then released into circulation by solubilization of plasma membrane

• Measure GGT or 5'-nucleotidase - if elevated alongside ALP = liver source
• If GGT and 5'-NT normal + high ALP = bone source
• Electrophoretic fractionation (most precise)

• Physiologic: Rapid bone growth (puberty) - can be 5-10x adult normal
• Bone disorders: Rickets, Paget's disease, osteosarcoma, bone metastases
• Benign transient hyperphosphatasemia of infancy (BTHI): ALP up to 10-40x normal in healthy infants/toddlers (<5 yr), resolves in 4 months; bone isoenzyme; associated with viral infections
• Others: Pregnancy (placental ALP), blood group O/B after fatty meal (intestinal ALP), hyperthyroidism

• ALP elevation >4x ULN primarily = cholestatic liver disease, infiltrative liver disease (cancer, amyloidosis), or bone disease
• <3x ULN can occur in virtually any liver disease
• ALP level does NOT distinguish intrahepatic vs extrahepatic cholestasis

---

3D. GAMMA-GLUTAMYL TRANSFERASE (GGT)

• Location: Endoplasmic reticulum, bile duct epithelium (more diffuse than ALP)
• Function: Transfers gamma-glutamyl groups from glutathione to amino acids; involved in amino acid transport
• Key role in pediatrics: Differentiating liver vs bone/physiologic ALP elevation (GGT is NOT elevated in bone disease)
• Normal: 0-45 U/L (age- and sex-dependent; neonates and infants have higher GGT)

---

3E. 5'-NUCLEOTIDASE (5'-NT)

• Enzyme located in canalicular membrane, similar distribution to liver ALP
• Elevated specifically in hepatic/biliary disease (NOT in bone disease)
• Used to confirm hepatic origin of elevated ALP when GGT measurement is unavailable
• Normal: 2-16 U/L
• Less readily available; GGT more commonly used as surrogate

---

3F. SERUM ALBUMIN

• Synthesis: Exclusively by hepatocytes (100%)
• Half-life: 18-20 days (~4% degraded/day)
• Normal: 3.5-5.0 g/dL
• Function: Maintain oncotic pressure, transport of bilirubin, fatty acids, hormones, drugs, Ca²⁺

---

3G. TOTAL PROTEIN AND ALBUMIN/GLOBULIN (A/G) RATIO

• Normal total protein: 6.0-8.0 g/dL
• A/G ratio normal: >1.0 (albumin > globulin)
• Reversed A/G ratio (<1): Low albumin (hepatic synthetic failure) + high globulins (immune activation, e.g., autoimmune hepatitis, chronic infections)
• Polyclonal hypergammaglobulinemia is characteristic of autoimmune hepatitis (IgG), primary biliary cholangitis (IgM), alcohol-associated liver disease (IgA)

---

3H. PROTHROMBIN TIME (PT) AND INR

• Synthesis of coagulation factors: ALL except Factor VIII synthesized in hepatocytes (Factors I, II, V, VII, IX, X, XI, XII, XIII, Protein C, S)
• Vitamin K-dependent factors: II, VII, IX, X, Protein C and S
• Factor VII has shortest half-life (~6 hours): First factor to fall in acute liver failure → PT/INR rises early
• PT/INR advantages over albumin: Reflects acute synthetic dysfunction (responds within hours to days)

• PT corrects with Vitamin K → Vitamin K deficiency (malabsorption, cholestasis with fat malabsorption)
• PT does NOT correct with Vitamin K → Hepatocellular synthetic failure

---

3I. SERUM AMMONIA

• Produced from: Intestinal bacterial metabolism of amino acids and proteins; kidneys
• Detoxified by: Liver via urea cycle (Krebs-Henseleit cycle) → urea (only the liver can do this)
• Normal: <35 μmol/L (venous); arterial more accurate
• Elevation (hyperammonemia) indicates: >80% hepatic parenchymal loss OR portosystemic shunting

• Must be measured on ice and processed within 30 min (false elevations from delayed processing)
• Do NOT use tourniquet; fist-clenching falsely elevates ammonia
• Elevated in urea cycle defects, organic acidemias (not always liver disease!)
• Ammonia level does NOT correlate well with severity of hepatic encephalopathy

---

3J. SERUM BILE ACIDS

• Most sensitive marker of hepatocellular function under physiologic conditions
• Elevated early in cholestatic conditions before bilirubin rises
• Total fasting serum bile acids: <10 μmol/L
• Postprandial elevation = impaired hepatic extraction
• Used in diagnosis of obstetric cholestasis and monitoring liver disease
• In neonates: Serum bile acids >10 μmol/L at >2 weeks of age = significant cholestasis

---

3K. SERUM LACTATE

• Elevated in liver disease due to:
  • Impaired hepatic lactate clearance/gluconeogenesis
  • Tissue hypoperfusion (ischemic hepatitis, ALF)
• Lactate >5 mmol/L in ALF = poor prognosis (used in King's College Criteria)
• Elevated lactate in mitochondrial hepatopathies (POLG1, DGUOK mutations) in infants

---

4. NORMAL REFERENCE RANGES IN CHILDREN

Key Age-Related Variations to Remember:

• Neonatal ALP and GGT are physiologically elevated (transferred placental/tissue enzymes)
• GGT is highest in the first week of life (reflects placental transfer) and normalizes by 6-8 months
• Pubertal growth spurt causes ALP elevation up to 5-10x adult normal (bone isoenzyme from osteoblastic activity)
• Neonatal bilirubin - physiological jaundice peaks Day 3-4 in term infants; direct bilirubin >1 mg/dL OR >20% of total bilirubin in ANY infant >2 weeks = PATHOLOGICAL and requires workup for cholestasis

---

5. CLASSIFICATION OF LIVER INJURY AND R-RATIO

Pattern-Based Classification:

R-Ratio (RUCAM Ratio) - HIGH YIELD FOR DILI DIAGNOSIS:

R = (ALT/ULN of ALT) ÷ (ALP/ULN of ALP)

"R > 5 defines hepatocellular injury, R < 2 cholestatic injury, and 5 > R > 2 mixed pattern" - Yamada's Textbook of Gastroenterology, 7th Ed

---

6. DETAILED INTERPRETATION OF EACH PARAMETER

Bilirubin - Causes of Elevation:

---

7. PATTERN-BASED DIFFERENTIAL DIAGNOSIS OF ABNORMAL LFTs

ABNORMAL LFTs
     |
     ├── HEPATOCELLULAR PATTERN (ALT/AST >> ALP)
     │    ├── Acute (marked elevation)
     │    │    ├── ALT/AST >100x ULN: Ischemic hepatitis, Acetaminophen toxicity
     │    │    ├── ALT/AST 10-100x ULN: Acute viral hepatitis (A,B,C,E), Wilson's ALF
     │    │    └── AST/ALT ≥2: Wilson's, ALD
     │    └── Chronic (mild-moderate elevation)
     │         ├── ALT>AST, AST/ALT<1: NAFLD, Chronic Hep B/C
     │         └── AIH, Wilson (consider in <40 yr)
     │
     ├── CHOLESTATIC PATTERN (ALP/GGT >> ALT/AST)
     │    ├── GGT HIGH → Hepatobiliary cholestasis
     │    │    ├── Neonates: Biliary atresia, Choledochal cyst, Neonatal sclerosing cholangitis
     │    │    ├── Older children: PSC (in IBD), Cholelithiasis, DILI
     │    │    └── All ages: Sepsis, TPN, Systemic illness
     │    └── GGT LOW/NORMAL → PFIC 1&2, Alagille syndrome, Benign Recurrent Intrahepatic Cholestasis (BRIC)
     │
     └── MIXED PATTERN
          └── DILI, Sepsis, EBV/CMV, Autoimmune overlap

---

8. STEPWISE APPROACH TO A CHILD WITH DERANGED LFTs

STEP 1: CONFIRM AND CHARACTERIZE
├── Repeat LFTs to confirm (especially mild isolated elevations)
├── Pattern recognition: Hepatocellular vs Cholestatic vs Mixed
└── Quantify severity: <3x, 3-10x, >10x, >100x ULN

STEP 2: TARGETED HISTORY
├── Age of onset (neonatal, infant, child, adolescent)
├── Jaundice: color of urine (dark = conjugated), stool (pale = cholestasis)
├── Drug/toxin history (ALL medications, herbal/Ayurvedic, supplements)
├── Travel, sick contacts, blood/body fluid exposure
├── Family history (metabolic liver disease, Wilson's, CF)
├── Dietary history (kwashiorkor, TPN)
└── Systemic disease (IBD → PSC, obesity → NAFLD, hemolysis)

STEP 3: PHYSICAL EXAMINATION
├── Growth parameters (failure to thrive)
├── Jaundice, scleral icterus
├── Hepatomegaly, splenomegaly
├── Liver texture (firm/hard = fibrosis/cirrhosis)
├── Signs of portal hypertension (splenomegaly, ascites, caput medusae, varices)
└── Kayser-Fleischer rings (Wilson's), xanthomata (cholestasis), acne/hirsutism (AIH)

STEP 4: FIRST-LINE INVESTIGATIONS
├── CBC + reticulocytes (hemolysis, hypersplenism)
├── Complete LFT panel
├── Viral serology: HBsAg, anti-HBs, anti-HBc, anti-HAV IgM, anti-HCV, HCV RNA
├── ANA, ASMA, anti-LKM1, anti-SLA (autoimmune hepatitis)
├── Serum ceruloplasmin, 24h urine copper (Wilson's >40 yr in DDx)
├── Abdominal ultrasound (biliary anatomy, liver echogenicity, spleen size)
└── PT/INR, albumin (synthetic function)

STEP 5: AGE-SPECIFIC ADDITIONS
├── NEONATE (<3 months): Direct bilirubin, TORCH serology, metabolic screen,
│   galactose-1-phosphate uridyltransferase, urine reducing substances,
│   alpha-1-antitrypsin level + phenotype, thyroid function,
│   hepatobiliary scintigraphy (HIDA scan), liver biopsy ± operative cholangiography
│   [Goal: Diagnose biliary atresia by 6-8 weeks → Kasai portoenterostomy]
│
├── INFANT/CHILD: Sweat chloride (CF), amino acid profile, urine organic acids,
│   acylcarnitine profile (metabolic workup)
│
└── ADOLESCENT: Serum ferritin/transferrin saturation (hemochromatosis),
    lipid panel/HbA1c/waist circumference (NAFLD/MASLD),
    slit-lamp exam (Wilson's), liver biopsy if indicated

STEP 6: LIVER BIOPSY - Indications
├── Definitive diagnosis of AIH, NASH, metabolic liver disease
├── Grading/staging of chronic hepatitis
├── Unexplained elevated LFTs after comprehensive workup
└── Pre-transplant evaluation

---

9. LFT PATTERNS IN COMMON PEDIATRIC DISEASES

9A. Viral Hepatitis

• Characteristic feature of viral hepatitis: ALT > AST (AST/ALT < 1) with marked elevation
• Fulminant hepatitis A: Rare (<0.1%); ALF with PT >1.5x unable to correct; high mortality without transplant

9B. EBV / CMV (Infectious Mononucleosis)

• Pattern: Mild hepatocellular (AST/ALT 2-5x ULN) + mild cholestasis (ALP mildly elevated)
• Atypical lymphocytosis on CBC (EBV)
• EBV-associated hepatitis: Jaundice rare but occurs in ~5%
• CMV hepatitis: In immunocompromised or neonates - more severe pattern
• Monospot test positive in children >5 yrs (less sensitive in younger children)
• Splenic rupture risk: Aminotransferase elevation in setting of EBV = contraindication to contact sports

9C. Autoimmune Hepatitis (AIH)

• Revised IAIHG Score or Simplified AIH Score used for diagnosis
• Treatment: Prednisolone + Azathioprine; excellent response → LFTs normalize

9D. Wilson's Disease

ALL of these together:
1. High TOTAL bilirubin (often >20 mg/dL)
2. LOW Alkaline Phosphatase (<40 U/L - paradoxically low)
3. AST/ALT ratio > 2-4
4. Coombs-negative hemolytic anemia (Cu²⁺ released from damaged hepatocytes lyses RBCs)
5. Renal failure (copper tubulotoxicity)
6. ALP/Bilirubin ratio < 4 is highly diagnostic

9E. Biliary Atresia (BA)

• Most common pediatric surgical cholestatic condition; incidence 1:10,000-15,000
• LFT Pattern: Cholestatic (Direct bilirubin elevated, GGT markedly elevated, ALP elevated)

• BA: GGT very high, pale stools consistently, no response to phenobarbital
• Neonatal Hepatitis: GGT may be lower, stools intermittently pigmented

9F. Choledochal Cyst

• Pattern: Obstructive cholestasis (mixed hepatocellular + cholestatic)
• Triad (classical, but present in only 20%): RUQ pain + jaundice + palpable RUQ mass
• LFTs: Elevated bilirubin (direct), elevated ALP, GGT; ALT/AST variable
• Diagnosis: Ultrasound, MRCP (best non-invasive)
• Treatment: Excision of cyst + hepaticojejunostomy (to prevent cholangiocarcinoma)

9G. Drug-Induced Liver Injury (DILI)

• Common pediatric offenders: Valproic acid, isoniazid, erythromycin (cholestatic), acetaminophen (hepatocellular necrosis), MTX (fibrosis), antifungals, herbal/Ayurvedic preparations

• RUCAM score used to assess causality (score 6-8 = probable DILI)
• Management: Stop offending drug; N-acetylcysteine for acetaminophen toxicity (best if given within 8-10 hours)

9H. NAFLD/MASLD (Non-Alcoholic/Metabolic-Associated Fatty Liver Disease)

• Most common cause of chronic liver disease in children globally (prevalence 3-12% in children, up to 70-80% in obese children)
• Nomenclature change (2023): NAFLD → MASLD (Metabolic-Associated Steatotic Liver Disease); NASH → MASH (Metabolic-Associated Steatohepatitis)

• Type 1 MASLD (adult type): Central obesity, metabolic syndrome, steatosis ± lobular inflammation ± ballooning
• Type 2 MASLD (pediatric-unique): Portal-based injury (portal inflammation, portal fibrosis) without ballooning - common in Hispanic/Asian boys

9I. Acute Liver Failure (ALF) in Children

• Definition: Evidence of acute liver injury + coagulopathy (PT >15s or INR >1.5 not correcting with Vitamin K) ± Hepatic Encephalopathy

• AST/ALT massively elevated (10-100x ULN) then FALLS as necrosis is complete ("enzyme burnout" = poor prognostic sign)
• Bilirubin rising
• PT/INR progressively worsening (best real-time marker)
• Albumin falls in prolonged ALF
• Ammonia rising (encephalopathy)
• ALP low in Wilson's ALF (as above)
• Lactate elevated (metabolic failure)

• King's College Criteria (KCC - Paracetamol): Arterial pH <7.3 or (PT >100s + Cr >300 μmol + Grade III/IV encephalopathy)
• PELD Score: <12 yrs; uses Bilirubin, INR, Albumin, Growth failure, age <1 yr
• MELD Score: >12 yrs; uses Bilirubin, INR, Creatinine
• Factor V Level <20% (French criteria): Best single prognostic marker in children with ALF

9J. Sepsis-Associated Liver Dysfunction

• Most common cause of conjugated jaundice in NICU/PICU
• Pattern: Cholestatic (ALP, GGT, direct bilirubin elevated)
• Mechanism: Bacterial toxins (LPS) impair bile canalicular transport (MRP2 downregulation), Kupffer cell activation, reduced hepatic blood flow
• ALT/AST mildly elevated
• Resolves with treatment of sepsis

9K. Dengue Hepatitis

• Very common in endemic areas; liver involvement in up to 80% of dengue
• Pattern: Mild-moderate hepatocellular (AST > ALT - distinguishes from other viral hepatitis)
• AST > ALT (AST/ALT > 1): Due to muscle involvement (dengue myositis) + shorter AST half-life
• AST typically 2-5x ULN; rarely >10x ULN (dengue severe hepatitis)
• Thrombocytopenia + transaminitis = characteristic combination
• Severe dengue hepatitis: AST/ALT >10x ULN; rare; associated with severe plasma leakage

9L. Typhoid (Enteric Fever)

• Mild transaminitis (ALT/AST 2-5x ULN) in 10-50% of typhoid fever
• Pattern: Mild hepatocellular
• Mechanism: Direct bacterial invasion of hepatocytes + endotoxemia
• Severe typhoid hepatitis rare; resolves with antibiotics
• ALT elevation out of proportion = consider typhoid hepatitis

9M. Hemolytic Disorders

• Pattern: Isolated unconjugated hyperbilirubinemia + elevated LDH + low haptoglobin + reticulocytosis
• AST may be mildly elevated (from RBC-derived AST release)
• ALT usually NORMAL (key differentiator from hepatocellular disease)
• Causes: Hereditary spherocytosis, G6PD deficiency, sickle cell disease, thalassemia, AIHA
• Important: In sickle cell disease, chronic RBC transfusions → iron overload → secondary liver disease

9N. Muscle Diseases (Isolated AST Elevation)

• Duchenne/Becker Muscular Dystrophy: AST elevated (cytoplasmic AST from muscle); ALT usually normal or mildly elevated; CK massively elevated
• Any myopathy/myositis/rhabdomyolysis: AST >> ALT; CK markedly elevated; aldolase elevated
• Diagnostic clue: Elevated CK + AST without ALT elevation = muscle source of AST
• Trap for MD exam: Pediatricians often get referred DMD boys for "elevated LFTs" - always check CK before labeling as liver disease!

9O. Bone Disorders (Isolated ALP Elevation)

---

10. SYNTHETIC FUNCTION AND PROGNOSTIC MARKERS

PELD = 4.80 × [ln(bilirubin mg/dL)] + 18.57 × [ln(INR)] - 6.87 × [ln(albumin g/dL)] + 4.36 (if <1 yr) + 6.67 (if growth failure)

Arterial pH <7.3 (independent of encephalopathy grade)
OR ALL THREE of:
- PT >100 seconds (INR >6.5)
- Serum creatinine >300 μmol/L
- Grade III-IV hepatic encephalopathy

---

11. DYNAMIC LIVER FUNCTION TESTS

---

12. ISOLATED LFT ABNORMALITIES

12A. Isolated Unconjugated Hyperbilirubinemia

Approach:
1. Check Reticulocytes, Hb, LDH, haptoglobin → Hemolysis?
   ├── YES: Hereditary spherocytosis, G6PD deficiency, sickle cell, AIHA, thalassemia
   └── NO:
       ├── Clinical picture + history → Fasting, physical stress (Gilbert's syndrome)
       │   [Gilbert's: >10% population; bilirubin rises with fasting, stress, illness; benign, no treatment]
       ├── Neonatal jaundice:
       │   ├── Day 1-3: Physiological (immature B-UGT + increased RBC turnover)
       │   ├── Prolonged >2 weeks: Breastmilk jaundice, hypothyroidism, Crigler-Najjar
       │   └── Marked >20 mg/dL in neonate: Crigler-Najjar Type I (kernicterus risk)
       └── Other: Drugs (rifampicin), ineffective erythropoiesis

12B. Isolated ALT Elevation

Most common clinical scenario encountered; must exclude non-hepatic causes:
1. Confirm: Repeat LFTs in 4-6 weeks
2. Drug/herbal history
3. Check: AST, CK, aldolase (muscle disease)
4. Screen common causes:
   ├── NAFLD (obese child): Metabolic workup, liver ultrasound
   ├── Celiac disease (anti-tTG IgA + IgA level): In children, celiac causes isolated ALT elevation
   ├── Thyroid disease (TSH): Hypothyroidism
   ├── Wilson disease (ceruloplasmin if <40 yr)
   └── Chronic viral hepatitis B/C (serology)

12C. Isolated AST Elevation

1. AST > ALT with elevated CK → MUSCLE SOURCE (DMD, myositis, rhabdomyolysis)
2. AST > ALT with normal CK:
   ├── Macro-AST (complex with IgG → prolonged half-life)
   ├── Hemolysis (RBC-derived AST)
   └── ALD (AST/ALT ≥ 2, AST <300 U/L)
3. AST > ALT in liver disease: Wilson's ALF, alcohol, cirrhosis

12D. Isolated ALP Elevation (with normal GGT)

→ BONE SOURCE (GGT normal = NOT liver cholestasis)
├── Physiologic pubertal growth (confirm by age, growth velocity)
├── Benign transient hyperphosphatasemia of infancy (age <5, ALP up to 40x normal, resolves 4 months)
├── Rickets (Vit D deficiency)
├── Paget's disease (adults)
├── Osteosarcoma, bone metastases
└── Hyperparathyroidism

12E. Isolated GGT Elevation

├── Early cholestatic liver disease (before ALP or bilirubin rise)
├── Alcohol-associated liver disease (very sensitive marker)
├── Drug induction (enzyme-inducing drugs: phenytoin, carbamazepine, rifampicin)
├── NAFLD
└── Pancreatic disease

12F. Hypoalbuminemia (Low Albumin)

├── Chronic hepatic disease (>80% destruction): Cirrhosis
├── Protein-losing enteropathy: Nephrotic syndrome, IBD, Ménétrier's
├── Malnutrition/Kwashiorkor
├── Protein-losing nephropathy
├── Acute phase reaction (sepsis, burns): albumin is negative acute phase protein
└── Malabsorption

---

13. CLINICAL CASE SCENARIOS

Case 1: Neonate, 6 weeks old, jaundiced, pale stools, dark urine

---

Case 2: 14-year-old obese boy, incidentally found elevated ALT 85 U/L, AST 65 U/L, GGT 78 U/L. No jaundice. Normal bilirubin, albumin, INR.

---

Case 3: 10-year-old, acute jaundice, dark urine, fever, abdominal pain. ALT 1500, AST 900, ALP 280, GGT 180, Total bilirubin 8 mg/dL, INR 1.1

---

Case 4: 16-year-old girl, jaundice, amenorrhea, acne, fatigue. ALT 380, AST 310, ALP 180, GGT 90, Total Bilirubin 5.2, Albumin 3.1, INR 1.4. Globulin 4.2 g/dL (polyclonal).

---

Case 5: 13-year-old, acute jaundice with hemolytic anemia (Hb 7.5), renal failure (Cr 2.4), ALT 800, AST 650, ALP 38 U/L (LOW!), Total bilirubin 24 mg/dL, INR 3.5, Coombs-negative hemolysis.

---

14. RECENT UPDATES AND GUIDELINE RECOMMENDATIONS

MASLD Nomenclature (2023 Multi-Society Consensus):

• NAFLD → MASLD (Metabolic-Associated Steatotic Liver Disease)
• NASH → MASH (Metabolic-Associated Steatohepatitis)
• Diagnostic criteria: Steatosis + at least 1 cardiometabolic risk factor (overweight/obesity, T2DM, hypertension, dyslipidemia, metabolic dysregulation)
• New category: MetALD for those with significant alcohol use + metabolic risk factors

NASPGHAN/AASLD Pediatric MASLD Guidelines (2023-2024):

• Screening: Children ≥9 years with obesity OR ≥10 years with overweight + risk factors
• Primary screening tool: Serum ALT (not routine ultrasound for screening)
• Liver biopsy if: ALT >2x ULN persisting >6 months + uncertainty about diagnosis or activity
• First-line treatment: Weight loss, lifestyle modification (no pharmacotherapy routinely approved)
• Vitamin E (400 IU/day) may be considered in biopsy-proven pediatric MASH

ESPGHAN Neonatal Cholestasis Guidelines (2022):

• Any direct bilirubin >1 mg/dL OR >20% of total bilirubin at age ≥2 weeks = Pathological - immediate workup
• First-line workup within 48h: Direct bilirubin fractionation, GGT, liver ultrasound, alpha-1-antitrypsin, thyroid function, urine culture, metabolic screen
• Biliary atresia workup urgently (HIDA + liver biopsy ± operative cholangiography) - Kasai by 8 weeks

AASLD Wilson's Disease Guidelines (updated 2022):

• Leipzig score ≥4 = diagnostic of Wilson's disease
• Serum ceruloplasmin + 24h urine copper + slit-lamp exam as initial workup
• Liver biopsy copper (>250 μg/g dry weight) remains gold standard
• Treatment: D-penicillamine or Trientine (chelation) OR zinc salts (maintenance)

NASPGHAN AIH Criteria (Recent):

• Simplified IAIHG Score: ANA/ASMA ≥1:40 (1pt), IgG >ULN (1pt), >1.1x ULN (2pt), compatible biopsy (1pt), typical biopsy (2pt), no viral hepatitis (2pt) → ≥6 = probable, ≥7 = definite
• Frontline: Prednisolone 2 mg/kg/day (max 60 mg) + Azathioprine 0.5-2 mg/kg/day

Pediatric ALF Network (PALFSG) Updates:

• Definition refined: PT >15s or INR >1.5 unable to correct with Vitamin K + evidence of acute liver disease + no known chronic liver disease
• Etiology in indeterminate in 40-50% of pediatric ALF cases
• NAC (N-acetylcysteine) infusion: Beneficial in non-acetaminophen ALF (PALFSG RCT showed improved transplant-free survival in non-acetaminophen ALF with INR <6 and no encephalopathy)

---

15. HIGH-YIELD TABLES

Table 1: AST vs ALT - Complete Comparison

Table 2: ALP vs GGT - Complete Comparison

Table 3: Conjugated vs Unconjugated Hyperbilirubinemia

Table 4: Hepatocellular vs Cholestatic Injury Pattern

Table 5: Acute vs Chronic Liver Disease

---

16. MNEMONICS AND MEMORY AIDS

MNEMONIC: "HALT" for causes of abnormal LFTs

---

MNEMONIC: "ABCDE" for Isolated ALT Elevation workup in children

---

MNEMONIC: "GAS PUMP" for causes of Hepatocellular injury pattern

---

"PFIC LOW GGT" Mnemonic:

---

Wilson's ALF - "WILSONS" Mnemonic:

---

"REACH" for Neonatal Cholestasis Workup:

---

AST/ALT Ratio Rules:

• "2 for ALD, 1 for Viral": AST/ALT ≥2 = Alcoholic; <1 = Viral/NAFLD
• "ALP below the belt in Wilson's": ALP LOW in Wilson's ALF
• "GGT guards the canaliculus; ALP also builds bones"
• "Albumin is slow (18-20 days), PT is fast (hours)" - use PT/INR for acute severity, albumin for chronic

---

17. MD/DNB EXAMINATION QUESTIONS

5-Mark Questions:

1. Define liver function tests. Why is the term "liver function tests" a misnomer? What tests truly reflect hepatic synthetic function?
   • Answer should cover: 18 main LFTs, only albumin/PT/INR truly measure function; AST/ALT measure hepatocyte damage not function; liver has enormous functional reserve
2. What is the significance of the AST/ALT ratio in clinical practice? Give three clinical situations where AST > ALT and their interpretation.
   • Answer: ALD (≥2:1, AST<300), Wilson's ALF, cirrhosis (>1:1), muscle injury (early >3:1 then normalizes)
3. How does bilirubin metabolism proceed in the hepatocyte? What is the clinical significance of delta bilirubin?
   • Answer: Full pathway from UCB-albumin → hepatocyte uptake → conjugation by B-UGT → MRP2 export; delta bilirubin (covalently bound to albumin) explains prolonged jaundice
4. Describe the R-ratio. How is it calculated and what is its clinical utility?
   • Answer: R = (ALT/ULN)/(ALP/ULN); >5 hepatocellular, <2 cholestatic, 2-5 mixed; used in DILI classification
5. What is benign transient hyperphosphatasemia of infancy? How would you differentiate it from cholestatic liver disease?

10-Mark Questions:

1. Describe the approach to a 4-week-old infant with jaundice, pale stools, and dark urine. Include the relevant investigations and their interpretation.
   • Cover: Neonatal cholestasis workup, biliary atresia vs neonatal hepatitis vs PFIC, role of GGT (high vs low), HIDA scan, liver biopsy, urgency of Kasai
2. Discuss the LFT pattern in Wilson's disease. How would you diagnose Wilson's disease presenting as acute liver failure in an adolescent?
   • Cover: The paradox of low ALP, high bilirubin, AST/ALT>2, Coombs-negative hemolysis, ALP/bilirubin<4; Leipzig scoring; urgent transplant evaluation
3. What are the causes and approach to a child with isolated elevated ALT discovered on routine blood testing?
4. Describe the hepatocellular vs cholestatic pattern of liver injury with examples, and explain how the R-ratio helps in classification.

Viva Questions (Commonly Asked in MD/DNB):

1. "Why is serum albumin not a good marker of acute liver failure?"
   • Half-life 18-20 days; acute injury does not have time to deplete albumin stores; use PT/INR or Factor V instead
2. "What is the only energy-dependent step in bilirubin metabolism?"
   • Canalicular export via MRP2 (ATP-dependent). This is why even in ALF, bilirubin is predominantly conjugated
3. "A child has markedly elevated ALP with normal GGT. What is your first diagnosis?"
   • Bone disorder (physiologic pubertal growth, benign transient hyperphosphatasemia, rickets, osteosarcoma) - GGT confirms/excludes liver origin
4. "Why is ALP paradoxically low in Wilson's ALF?"
   • Copper inhibits ALP activity; copper accumulation in canalicular membranes impairs ALP; also ongoing hemolysis depletes zinc (ALP is a zinc metalloenzyme); ALP/Bilirubin <4 is pathognomonic
5. "What is the significance of unconjugated bilirubin never appearing in urine?"
   • UCB is tightly albumin-bound → MW too large for glomerular filtration; only conjugated (water-soluble, free) bilirubin is filtered and appears in urine; bilirubinuria = conjugated hyperbilirubinemia
6. "What is macro-AST and its clinical importance?"
   • AST bound to IgG forming high molecular weight complex → prolonged serum half-life → persistent isolated AST elevation → avoid unnecessary liver workup; polyethylene glycol precipitation test to detect
7. "Name the LFT parameters used in PELD score."
   • Bilirubin (total), INR (PT), Albumin, plus age <1 year and growth failure
8. "What is Factor V's role in assessing prognosis in pediatric ALF?"
   • Factor V level <20% (French criteria) = poor prognosis requiring transplant; synthesized exclusively in hepatocytes; short half-life; not Vitamin K-dependent (unlike factors II, VII, IX, X)
9. "A child's GGT is low despite obvious cholestasis. What diagnoses should you consider?"
   • PFIC type 1 (FIC1/ATP8B1 mutation) and PFIC type 2 (BSEP/ABCB11 mutation); Alagille syndrome (may have low/normal GGT); also benign recurrent intrahepatic cholestasis (BRIC types 1&2)
10. "What is the de Ritis ratio and when is it used?"
    • AST/ALT ratio; introduced by Fernando de Ritis; >2 in ALD; <1 in viral hepatitis/NAFLD; rising toward and beyond 1 indicates developing cirrhosis in chronic liver disease

---

18. KEY TAKE-HOME MESSAGES AND EXAM PEARLS

1. "LFTs" is a misnomer - most tests (AST, ALT, ALP) measure liver injury, NOT liver function. True function = Albumin + PT/INR + Factor V.
2. AST/ALT < 1 = viral hepatitis, NAFLD. AST/ALT ≥ 2 = alcoholic liver disease or Wilson's ALF.
3. ALP high + GGT normal = bone source (physiologic puberty, rickets, BTHI, osteosarcoma) - NOT liver disease.
4. ALP LOW in Wilson's ALF - a paradox that is pathognomonic; ALP/Bilirubin ratio <4 diagnostic.
5. PFIC 1 and 2 = LOW GGT cholestasis. High GGT cholestasis = biliary atresia, PSC, PFIC-3, drug-induced.
6. Neonatal direct bilirubin >1 mg/dL or >20% of total = PATHOLOGICAL at age ≥2 weeks - immediate workup; time-critical for biliary atresia (Kasai by 6-8 weeks).
7. Isolated elevated AST in a child + elevated CK = muscle disease (DMD) - don't miss this by only checking ALT.
8. Celiac disease causes isolated ALT elevation in children - always check anti-tTG IgA in unexplained pediatric ALT elevation.
9. Albumin has a half-life of 18-20 days = poor acute marker; PT/INR reflects acute synthetic function (Factor VII half-life = 6 hours).
10. Serum ammonia must be collected on ice and processed within 30 minutes; avoid tourniquet and fist-clenching to prevent false elevations.
11. Delta bilirubin (covalently albumin-bound conjugated bilirubin, t½ = 18-20 days) explains why jaundice persists for weeks after resolution of biliary obstruction.
12. R-ratio (ALT/ULN ÷ ALP/ULN): >5 = hepatocellular, <2 = cholestatic, 2-5 = mixed. Essential for DILI classification.
13. GGT is the most sensitive marker of cholestasis and alcohol use; NOT elevated in bone disease.
14. ALP is physiologically very high in children during puberty (up to 5-10x adult upper limit) due to osteoblastic bone-ALP - do not misinterpret as liver disease.
15. Factor V < 20% (French criteria) = best single prognostic marker for transplant need in pediatric ALF.
16. MRP2 (multidrug resistance-associated protein 2) is the only ATP-dependent (energy-requiring) step in bilirubin metabolism - explains conjugated hyperbilirubinemia in ALF.
17. MASLD (2023 new name for NAFLD) - most common chronic liver disease in obese children; screen with ALT in children ≥9 years with obesity; biopsy if ALT >2x ULN for >6 months.
18. In dengue: AST > ALT (unlike other viral hepatitis where ALT > AST) - due to coexisting muscle involvement.

---